Physical and Psychological Effects of Different Temperature-controlled Breast Prostheses on Patients With Breast Cancer

February 1, 2019 updated by: Zhenqi Lu, Fudan University

Physical and Psychological Effects of Different Temperature-controlled Breast Prostheses on Patients With Breast Cancer During Rehabilitation: a Randomized Controlled Study

Breast loss causes negative influence on women physically, psychologically and socially. Breast prosthesis can improve patient's figure externally, increase self-confidence, thus improving quality of life. The objective was to understand the knowledge regarding breast prostheses in breast cancer patients, evaluate the quality of life of patients wearing different types of breast prostheses and to compare the physical and psychological effects of different temperature-controlled breast prostheses on patients. The investigators designed a randomized control study in one cancer center in Shanghai. In the first 6 weeks of the study, self-adhesive breast prostheses and conventional breast prostheses were used in the intervention and control group, respectively. In the later 6 weeks, the breast prostheses used were switched into another kind. Several dimensional parameters were examined by different questionnaires at the end of both 6th and 12th week including scars and skin, survey of breast prosthesis knowledge, survey assessing the comfort and practicality of breast prostheses, quality of life instruments for cancer patients and body image scale. The investigators expected that women would be satisfied with the temperature-controlled breast prosthesis and were more willing to choose self-adhesive breast prostheses.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Breast loss causes negative influence on women physically, psychologically and socially. Breast prosthesis can improve patient's figure externally, increase self-confidence, thus improving quality of life. Prospective study of different breast prostheses has not yet been performed in China. The objective was to understand the knowledge regarding breast prostheses in breast cancer patients, evaluate the quality of life of patients wearing different types of breast prostheses and to compare the physical and psychological effects of different temperature-controlled breast prostheses on patients. The investigators designed a randomized control study in one cancer center in Shanghai. Eligible participants were randomized into either intervention or control group. In the first 6 weeks of the study, self-adhesive breast prostheses and conventional breast prostheses were used in the intervention and control group, respectively. In the later 6 weeks, the breast prostheses used were switched into another kind. Several dimensional parameters were examined by different questionnaires at the end of both 6th and 12th week including scars and skin, survey of breast prosthesis knowledge, survey assessing the comfort and practicality of breast prostheses, quality of life instruments for cancer patients and body image scale. The investigators expected that women would be satisfied with the temperature-controlled breast prosthesis and were more willing to choose self-adhesive breast prostheses.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
30

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • undergoing unilateral mastectomy due to breast cancer confirmed by histological examination
  • had undergone mastectomy at least six months prior to the start of the study or patients who completed radiation therapy at least two months prior
  • without evidence of postoperative relapse
  • wearing conventional (non-adhesive) breast prostheses
  • without abnormal skin or skin lesions
  • patients without progressive lymphedema;
  • interested in conventional and self-adhesive breast prostheses.

Exclusion Criteria:

  • with incomplete healing of their surgical wounds
  • undergoing chemoradiotherapy or who received chemoradiotherapy less than two months prior to the beginning of the study
  • with skin conditions that do not meet the requirements
  • whose remaining breast is not within the study's size range
  • with significant life changes during the study, including divorce, unemployment or depression; 6) relapsed during the observation period
  • had a reaction to the first skin test and who were not able to receive the second skin test.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Self-adhesive Group
The participants used the adhesive breast prosthesis that adheres to the skin.
Other: different temperature-controlled breast prostheses
Two types of temperature-controlled breast prostheses were applied to patients in each group
Active Comparator: Conventional Group
The participants used the conventional breast prosthesis that was placed inside a bra and did not directly adhere to the skin.
Other: different temperature-controlled breast prostheses
Two types of temperature-controlled breast prostheses were applied to patients in each group

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Participants' skin condition
Time Frame: 12 weeks
Scars and skin conditions: these examinations were performed by the same investigator.
12 weeks
Participants' knowledge with regard to the breast prosthesis
Time Frame: 12 weeks
A self-designed questionnaire covering a total of 11 items was used, including sources the patients used to obtain information on breast prostheses, reasons for choosing the breast prosthesis, its type and price, and the patient's feelings about wearing their breast prosthesis.
12 weeks
Participants' feeling of the comfort and practicality of breast prostheses
Time Frame: 12 weeks
A self-designed questionnaire covering a total of 10 items regarding the breast prostheses was used, including skin adhesion, practicality in daily life, maintainability, comfort, natural fit, contact, safety, and effects on the shoulder and back
12 weeks
Measurement of Quality of life of the participants
Time Frame: 12 weeks
We use breast cancer (QLICP-BR) to measure patients' quality of life.the QLICP-BR selected the following 37 items: 6 items in physical functional dimensions (PH), 12 items in psychological functional dimensions (PS), 8 items in symptoms and side effects dimensions (ST), 10 items in social functional dimensions (SOs) and 1 item in overall health condition.
12 weeks
Measurement of Body Image of the participants
Time Frame: 12 weeks
The Body Image Scale (BIS) is a self-assessment scale designed to assess cancer patients' perceptions of their appearance and identify any changes to those perceptions resulting from a disease or a treatment.
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Fudan University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • 1.Huang ZZ, Chen WQ, Wu CX, et al. Incidence and mortality of female breast cancer in China--- a report from 32 Chinese cancer registries, 2003-2007. Tumor, 2012, 32(6):435-439. 2.Li N, Zheng RS, Zhang SW, et al. Analysis and prediction of breast cancer incidence trend in China. Chinese Journal of Preventive Medicine, 2012, 8(46):703-707. 3.Huang ZZ, Chen WQ, Wu CX, et al. The trends of female breast cancer incidence and mortality in Beijing, Shanghai, Linzhou and Qidong in China. Tumor, 2012, 32(8): 605-608. 4.Li MF, Wang XH, Zhao XY. Research of breast cancer incidence. Journal of China Traditional Chinese Medicine Information, 2011, 15(3): 76. 5.Chen W, Wang CS, Zhang W. Comparison of breast-conserving therapy and mastectomy. Chinese Primary Medicine, 2013,2(20):255-257. 6.Zhang BN, Yu ZH. Key problems in breast-conserving surgeries. Chinese Journal of Oncology, 2001,23(6):523-524. 7.Zhang BN, Zhang B, Tang ZH, et al. 10-year changes and development of surgical treatment for breast cancer in China. Chinese Journal of Oncology, 2012,8(34): 582-587. 8.Zhang YS, Liu YJ. A review for the surgical management of breast cancer and the latest developments. Modern Oncology, 2015,5(23):719-722. 9.Song YL, Zhang KM. Development of psychological nursing in postoperative breast cancer patients who lost their breasts. Medical Equipment, 2015,2(28):125-126. 10.Sun LQ. Cognitive study on prostheses wearing in postoperative breast cancer patients who lost their breasts. Journal of Qilu Nursing, 2010,16(21):48-49. 11.Xie SH. Physical and psychological influence of breast loss on postoperative breast cancer patients and nursing strategy. Chinese General Practice Nursing, 2014,12(4):351-352. 12.Ding ZY. Perioperative nursing of breast cancer patients who undergone DIEP. Nursing Journal of Chinese People's Liberation Army, 2006,12(24):67-68. 13.Cao RJ. Investigation of sexual status of patients who undergone mastectomy. Today Nurse, 2011(6):114-116. 14.Ren HL, Jia XJ, Wang Q. Correlation between postoperative self-image and coping style of patients with breast cancer. Chinese Journal of Modern Nursing, 2014,20(11):1274-1277. 15.Li R. Effective analysis of different surgical treatments in early-stage breast cancer. Chinese Youjiang Medical Journal, 2013,41(1):4-6. 16.Zhang HX. Analysis of influential factors on quality of life of patients with breast cancer. Nursing Journal of Chinese People's Liberation Army, 2007,24(3):45-46. 17.Huang LP, Xiong BQ. Application of high quality nursing on prostheses wearing in postoperative patients with breast cancer. Journal of Yangtze University(Natural Science Edition), 2013,10(6):42-43. 18.Gallagher P, Buckmaster A, O'Carroll S, et al. Experiences in the provision, fitting and supply of external breast prostheses: findings from a national survey. European Journal of Cancer Care,2009,6(18):556-568. 19.Thijs-Boer FM, Thijs JT, Van HB. Conventional or adhesive external breast prosthesis? A prospective study of the patients' preference after mastectomy. Cancer Nurs,2001,3(24):227-230. 20.Kubon TM, McClennen J, MI Fitch, et al. A mixed-methods cohort study to determine perceived patient benefit in providing custom breast prostheses. Current Oncology, 2012, 2(19):43-52.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 10, 2016

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 31, 2017

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 30, 2017

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 25, 2019

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 1, 2019

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 5, 2019

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 5, 2019

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 1, 2019

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • IRB1403133-2

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings